Literature DB >> 23906912

Packaging shRNA retroviruses.

Kenneth Chang, Krista Marran, Amy Valentine, Gregory J Hannon.   

Abstract

To silence a mammalian gene by RNAi using an encoded trigger, a short-hairpin RNA (shRNA) is integrated into the host cell genome as a stable transgene. Target cells are infected with viral plasmid containing shRNA inserted into the vector backbone. Before infection, the plasmid is transfected into a packaging cell line, which provides the trans-acting factors necessary for virus production. These include, minimally, capsid proteins and reverse transcriptase, but they can also include other regulatory factors (e.g., tat for some lentiviral vectors). It is critical to choose the correct packaging cell system for the viral backbone to be used. The packaging cell also defines the host range of the virus, depending on the envelope protein that it expresses. Ecotropic viruses are limited to rodent hosts, whereas amphotropic viruses have a broader host range that also includes humans. Often, investigators will express a nonretroviral envelope, such as vesicular stomatitus virus (VSV) glycoprotein, to enhance virus stability and host range and to enable viruses to be concentrated following production. Although viruses carrying shRNAs are packaged almost identically to viruses carrying protein-encoding genes, one twist is worth noting. shRNAs are efficiently cleaved by the host RNAi biogenesis machinery, which can reduce the level of viral genomic RNAs and consequently viral titers. Therefore, titers can be enhanced by cotransfecting the viral plasmid with a small interfering RNA (siRNA) that targets DGCR-8/Pasha, which is a core microRNA (miRNA) biogenesis component. siRNAs against Drosha can also be used.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23906912     DOI: 10.1101/pdb.prot076448

Source DB:  PubMed          Journal:  Cold Spring Harb Protoc        ISSN: 1559-6095


  6 in total

1.  Creating transgenic shRNA mice by recombinase-mediated cassette exchange.

Authors:  Prem K Premsrirut; Lukas E Dow; Youngkyu Park; Gregory J Hannon; Scott W Lowe
Journal:  Cold Spring Harb Protoc       Date:  2013-09-01

2.  Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Authors:  Paul A Beavis; Melissa A Henderson; Lauren Giuffrida; Jane K Mills; Kevin Sek; Ryan S Cross; Alexander J Davenport; Liza B John; Sherly Mardiana; Clare Y Slaney; Ricky W Johnstone; Joseph A Trapani; John Stagg; Sherene Loi; Lev Kats; David Gyorki; Michael H Kershaw; Phillip K Darcy
Journal:  J Clin Invest       Date:  2017-02-06       Impact factor: 14.808

3.  Single-Chromosomal Gains Can Function as Metastasis Suppressors and Promoters in Colon Cancer.

Authors:  Anand Vasudevan; Prasamit S Baruah; Joan C Smith; Zihua Wang; Nicole M Sayles; Peter Andrews; Jude Kendall; Justin Leu; Narendra Kumar Chunduri; Dan Levy; Michael Wigler; Zuzana Storchová; Jason M Sheltzer
Journal:  Dev Cell       Date:  2020-02-24       Impact factor: 12.270

4.  An optimized retroviral toolbox for overexpression and genetic perturbation of primary lymphocytes.

Authors:  Lieve E H van der Donk; Jet van der Spek; Tom van Duivenvoorde; Marieke S Ten Brink; Teunis B H Geijtenbeek; Coenraad P Kuijl; Jeroen W J van Heijst; Louis S Ates
Journal:  Biol Open       Date:  2022-03-01       Impact factor: 2.422

5.  Generating Single Cell-Derived Knockout Clones in Mammalian Cells with CRISPR/Cas9.

Authors:  Christopher J Giuliano; Ann Lin; Vishruth Girish; Jason M Sheltzer
Journal:  Curr Protoc Mol Biol       Date:  2019-09

6.  Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies.

Authors:  Devon A Lukow; Erin L Sausville; Pavit Suri; Narendra Kumar Chunduri; Angela Wieland; Justin Leu; Joan C Smith; Vishruth Girish; Ankith A Kumar; Jude Kendall; Zihua Wang; Zuzana Storchova; Jason M Sheltzer
Journal:  Dev Cell       Date:  2021-08-04       Impact factor: 12.270

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.